Frequency and clinical significance of a variety of autoantibodies in patients with definite infective endocarditis

J Clin Rheumatol. 2012 Mar;18(2):67-70. doi: 10.1097/RHU.0b013e318247caf0.

Abstract

Background: Patients with infective endocarditis (IE) may present rheumatic manifestations concurrent with autoantibodies with low specificity, thus increasing misdiagnosis. Frequency of autoantibodies with high specificity remains unknown.

Methods: Nineteen patients with definite IE were studied for low specificity (rheumatoid factor [RF], antinuclear antibodies, anti-Ro/SSA, anti-La/SSB, anti-ribonucleoproteins (anti-RNP) anticardiolipin [aCL], and anti-β2 glycoprotein 1) and high specificity (anti-cyclic citrullinated peptides [anti-CCPs], anti-double-stranded DNA, anti-Sm, anti-Scl70, and anticentromere) antibodies.

Results: Frequency of RF was 68%; antinuclear antibodies, 47%; aCL/IgG, 58%; aCL/IgM, 47%; anti-β2 glycoprotein 1/IgG, 5%; and anti-Ro/SSA, 5%. Three patients had antiphospholipid syndrome-related antibodies in high titers, one of them also having pulmonary embolism. Except for anti-CCP (1 patient), other highly specific antibodies were absent.Rheumatoid factor of 100 UI/mL or greater and multifocal endocarditis were independently associated with in-hospital mortality.

Conclusions: Clinicians should need to be aware about the common presence of a variety of antibodies with low specificity but also the exceptional occurrence of anti-CCP antibodies in IE. Special attention to multifocal endocarditis and high RF is also suggested.

MeSH terms

  • Adult
  • Antibody Specificity
  • Autoantibodies / analysis*
  • Biomarkers
  • Cardiovascular Diseases* / etiology
  • Cardiovascular Diseases* / immunology
  • Diagnostic Errors / prevention & control*
  • Endocarditis* / complications
  • Endocarditis* / diagnosis
  • Endocarditis* / immunology
  • Female
  • Hospital Mortality
  • Humans
  • Male
  • Middle Aged
  • Peptides, Cyclic / immunology
  • Pulmonary Embolism* / etiology
  • Pulmonary Embolism* / immunology
  • Pulmonary Embolism* / mortality
  • beta 2-Glycoprotein I / immunology

Substances

  • Autoantibodies
  • Biomarkers
  • Peptides, Cyclic
  • beta 2-Glycoprotein I
  • cyclic citrullinated peptide